期刊文献+

唑来膦酸影响骨密度效果的系统评价 被引量:1

Effectiveness of Zoledronic Acid Increasing Bone Mineral Density: A Systematic Review
下载PDF
导出
摘要 目的系统评价唑来膦酸影响骨密度的临床效果。方法计算机检索Cochrane Ce4ntral Register of Controlled Trials,OTA,AAOS,High Wire Press,Springer Link,MEDLINE,EMBASE,CINAHL,ISI Web of Science,CNKI,VIP,万方数据库和中国生物医学文献数据库(CBM)并辅以手工检索关于唑来膦酸影响骨密度的随机对照试验(RCT)。结果共纳入7个RCT。3个RCT显示唑来膦酸可增加腰椎骨密度增加率,3个RCT显示唑来膦酸可增加股骨颈骨密度增加率,4个RCT显示唑来膦酸可增加腰椎骨密度。结论唑来膦酸对增加全身多处骨密度有一定效果。 Objective To evaluate the effectiveness of zoledronic acid increasing bone mineral density (BMD).Methods The Cochrane Central Register of Controlled Trials,OTA,AAOS,High Wire Press,Springer Link,MEDLINE,EMBASE,CINAHL,ISI Web of Science,CNKI,VIP,Wan fang Data,CBM were searched by computer and hand for randomized controlled trials(RCT) of zoledronic acid influencing the BMD.Results Seven RCTs were included.Three studies indicated that zoledronic acid improved lumbar spine BMD increasing-rate.Three studies indicated that zoledronic acid improved femoral neck BMD increasing-rate.Four studies indicated that zoledronic acid increased lumbar spine BMD.Conclusion Zoledronic acid is effective in increasing bone mineral density of muhiple parts of the body.
出处 《医学综述》 2014年第18期3387-3389,共3页 Medical Recapitulate
关键词 唑来膦酸 骨密度 随机对照试验 系统评价 META分析 Zoledronic acid Bone mineral density Randomized controlled trial Systematic review Meta analysis
  • 相关文献

参考文献4

二级参考文献26

  • 1白小清,王伯初.第3代双膦酸盐类药物——唑来膦酸[J].中国药业,2006,15(9):27-29. 被引量:7
  • 2崔巍,彭六保.唑来膦酸的临床应用研究进展[J].中南药学,2006,4(6):467-469. 被引量:19
  • 3吕靖,马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述,2007,13(1):62-63. 被引量:37
  • 4Papapoulos SE,Landman JO,Bijvoet OL,et al.The use of bisphosphonate in the treatment of osteoporosis[J].Bone,1992,13(1):41.
  • 5Nguyen ND,Eisman JA, Nguyen TV. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res, 2006,21 ( 2 ) : 340 -349.
  • 6Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 2007,356 : 1809-1822.
  • 7Siris ES, Harris ST, Rosen C J, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc,2006,81 : 1013-1022.
  • 8Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab,2010,95:4380-4387.
  • 9Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf,2007,30:755-763.
  • 10Roelofs AJ, Jauhiainen M, Monkkonen H, et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haemato1,2009 ,144 :245-250.

共引文献78

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部